DKC1 and acute myeloid leukemia: Currently, a clinical trial is underway to assess the potential of Pyrazofurin, a molecule acknowledged for targeting orotodine‐5′‐monophosphate‐decarboxylase and inhibiting DKC1, as a treatment for AML.175